Perrigo Company PLC Market Cap ($2.01 Billion)
Market Cap & Net Worth: Perrigo Company PLC (PRGO)
Perrigo Company PLC market cap. Perrigo Company PLC (NYSE:PRGO) has a market capitalization of $2.01 Billion ($2.01 Billion) as of November 1, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #5913 globally and #1933 in its home market, demonstrating a -3.60% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Perrigo Company PLC's stock price $15.78 by its total outstanding shares 138367770 (138.37 Million). Also see cash efficiency ratio of Perrigo Company PLC for how efficiently the company converts equity into cash flow.
Perrigo Company PLC Market Cap History (2015–2026)
Perrigo Company PLC market cap history from 2015 to 2026. Data shows change from $16.68 Billion to $2.18 Billion (-17.83% CAGR). Check PRGO live share price for real-time trading data and today's change.
Index Memberships
Perrigo Company PLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.45 Trillion | 0.06% | #20 of 24 |
|
S&P Midcap 400
MID
|
$3.34 Trillion | 0.13% | #375 of 401 |
Weight: Perrigo Company PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Perrigo Company PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Perrigo Company PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Perrigo Company PLC net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.45x
Perrigo Company PLC's market cap is 0.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $9.65 Billion | $5.28 Billion | -$4.01 Billion | 1.83x | N/A |
| 2017 | $10.19 Billion | $4.95 Billion | $119.60 Million | 2.06x | 85.18x |
| 2018 | $4.58 Billion | $4.73 Billion | $131.00 Million | 0.97x | 34.93x |
| 2019 | $6.21 Billion | $3.87 Billion | $146.10 Million | 1.60x | 42.49x |
| 2020 | $5.46 Billion | $4.09 Billion | -$162.60 Million | 1.34x | N/A |
| 2021 | $4.87 Billion | $4.14 Billion | -$68.90 Million | 1.18x | N/A |
| 2022 | $4.39 Billion | $4.45 Billion | -$140.60 Million | 0.99x | N/A |
| 2023 | $4.28 Billion | $4.66 Billion | -$12.70 Million | 0.92x | N/A |
| 2024 | $3.56 Billion | $4.37 Billion | -$171.80 Million | 0.81x | N/A |
| 2025 | $1.93 Billion | $4.25 Billion | -$1.43 Billion | 0.45x | N/A |
Competitor Companies of PRGO by Market Capitalization
Companies near Perrigo Company PLC in the global market cap rankings as of November 1, 2026. Also see total assets of Perrigo Company PLC for a full breakdown of the balance sheet.
Key companies related to Perrigo Company PLC by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Perrigo Company PLC (2015–2026)
Market capitalization of Perrigo Company PLC from 2015 to today. Between 2015 and today, Perrigo Company PLC's market cap moved from $16.68 Billion to $ 2.18 Billion, with a yearly change of -17.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.18 Billion | +13.36% |
| 2025 | $1.93 Billion | -45.86% |
| 2024 | $3.56 Billion | -16.92% |
| 2023 | $4.28 Billion | -2.47% |
| 2022 | $4.39 Billion | -9.78% |
| 2021 | $4.87 Billion | -10.95% |
| 2020 | $5.46 Billion | -11.97% |
| 2019 | $6.21 Billion | +35.65% |
| 2018 | $4.58 Billion | -55.08% |
| 2017 | $10.19 Billion | +5.58% |
| 2016 | $9.65 Billion | -42.14% |
| 2015 | $16.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Perrigo Company PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.01 Billion USD |
| MoneyControl | $2.01 Billion USD |
| MarketWatch | $2.01 Billion USD |
| marketcap.company | $2.01 Billion USD |
| Reuters | $2.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Perrigo Company PLC
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and ora… Read more